International Journal of Science and Research Archive

eISSN: 2582-8185

Cross Ref DOI: 10.30574/ijsra

Journal homepage: https://ijsra.net/

(Review Article)

Check for updates

A comprehensive review of AI applications in personalized medicine

Chioma Anthonia Okolo [1,*], Tolulope Olorunsogo [2] and Oloruntoba Babawarun [3]

[1] *Federal Medical Centre, Asaba, Delta State, Nigeria.*
[2] *Independent Researcher, Nebraska USA.*
[3] *Global Future Redemption Empowerment Foundation, Oyo State, Nigeria.*

International Journal of Science and Research Archive, 2024, 11(01), 2544–2549

Publication history: Received on 14 January 2024; revised on 25 February 2024; accepted on 27 February 2024

Article DOI: https://doi.org/10.30574/ijsra.2024.11.1.0338

Abstract

Personalized medicine, propelled by advances in genomic and molecular understanding, is undergoing a transformative paradigm shift, and artificial intelligence (AI) is emerging as a pivotal catalyst in this evolution. This comprehensive review explores the intersection of AI and personalized medicine, aiming to provide a holistic overview of the current landscape, challenges, and future directions. The review delves into AI applications across key domains, including genomic medicine, disease diagnosis, risk prediction, patient stratification, and clinical trials. Special attention is given to the ethical considerations inherent in AI-powered personalized medicine, addressing issues of privacy, informed consent, transparency, and fairness. The narrative concludes by highlighting persistent challenges, anticipating future innovations, and advocating for collaborative endeavors to ensure the ethical implementation of AI in personalized medicine. This nuanced analysis serves as a valuable reference for researchers, healthcare professionals, policymakers, and stakeholders engaged in navigating the intricate interplay of AI and personalized healthcare.

Keywords: AI; Applications; Personalized; Medicine

1. Introduction

Personalized medicine represents a revolutionary approach to healthcare that seeks to tailor medical treatments to the unique characteristics of individual patients. It transcends the traditional one-size-fits-all model by considering variations in genetic makeup, lifestyle, and environmental factors. This approach aims to optimize therapeutic interventions, minimize adverse effects, and improve overall patient outcomes (Jameson and Longo, 2015; Collins and Varmus, 2015). The core principles of personalized medicine involve utilizing a patient's unique genetic, molecular, and clinical information to guide medical decisions (Hamburg and Collins, 2010). This approach emphasizes the importance of understanding the individual's biological makeup to prescribe treatments that are most likely to be effective and well-tolerated (Ginsburg and McCarthy, 2001).

The evolution of personalized medicine can be traced from traditional medical practices to the current era of advanced molecular and genetic understanding. Traditional medicine focused on treating symptoms without considering individual variability. The advent of genomics and technological advancements has transformed this paradigm, enabling a more nuanced and targeted approach to healthcare (Hamburg and Collins, 2010). The significance of personalized medicine lies in its potential to revolutionize healthcare outcomes. By tailoring treatments to individual characteristics, it addresses the limitations of generic interventions, offering a more precise and effective therapeutic approach (Duffy, 2016). This shift has profound implications for disease prevention, diagnosis, and treatment. Central to personalized medicine is the concept of tailoring treatments based on an individual's genetic makeup, molecular profile, and other relevant characteristics (Verma, 2012). This approach recognizes the inherent variability among patients, allowing for customized interventions that optimize efficacy and minimize adverse effects. Advancements in molecular and genetic

* Corresponding author: Chioma Anthonia Okolo

understanding have been instrumental in shaping personalized medicine (Seyhan and Carini, 2019). The deciphering of the human genome, coupled with technological breakthroughs in genomics, has provided unprecedented insights into the genetic basis of diseases and individual variability.

The emergence of artificial intelligence (AI) represents a paradigm shift in healthcare, with profound implications for personalized medicine (Topol, 2019). AI encompasses machine learning algorithms and computational models that can analyze vast amounts of data, identify patterns, and generate insights to inform medical decision-making (Esteva et al.,2019). AI's introduction to healthcare has transformed the landscape by offering tools and technologies that enhance diagnostic accuracy, treatment efficacy, and overall patient care. From image recognition in radiology to predictive modeling for disease outcomes, AI has demonstrated its potential to revolutionize healthcare practices (Char et al., 2018). The evolution of AI applications in medicine has witnessed a progression from basic diagnostic support to complex predictive modeling and treatment optimization. AI algorithms have matured to handle diverse datasets, including genomic and clinical information, enabling more nuanced and personalized medical interventions. The motivation for integrating AI into personalized medicine stems from the need to process and interpret the vast and intricate datasets inherent in individualized healthcare (Johnson et al., 2021). AI's ability to uncover patterns in biological and genetic data makes it a powerful tool for deriving actionable insights and optimizing treatment strategies. The complexity of biological and genetic data in personalized medicine necessitates advanced analytical tools, and AI excels in unraveling the intricacies of these datasets (Keerthana, et al., 2020). Machine learning algorithms can identify subtle patterns and associations, contributing to a deeper understanding of individual variability. AI's integration into personalized medicine enhances predictive modeling by incorporating a multitude of factors, including genetic, clinical, and lifestyle data (Krittanawong et al., 2018). This facilitates the optimization of treatment plans, ensuring that interventions are tailored to the individual's unique characteristics for improved outcomes. This comprehensive exploration of the background and the rise of AI in personalized medicine lays the foundation for understanding the synergies between these two transformative fields. The references cited provide a robust basis for further exploration and in-depth analysis in subsequent sections.

2. AI in genomic medicine

The advent of genomic medicine, catalyzed by the Human Genome Project, has provided an unprecedented influx of genetic data (Green et al., 2020; Oladipo et al., 2024). AI plays a pivotal role in processing and interpreting this vast amount of genomic information. Machine learning algorithms excel in identifying genetic variations, annotating genomic data, and predicting the functional implications of these variations (Schuster, 2008; Shendure and Ji, 2008).

AI-driven tools have revolutionized genomic sequencing processes. These tools, powered by machine learning algorithms, enable more accurate variant calling, annotation, and interpretation of genomic data (Poplin et al., 2018; Nwankwo et al., 2024). The application of AI in genomic sequencing enhances the identification of disease-related genetic variants and contributes to a deeper understanding of the genomic basis of various conditions (Zou and Huss, 2018). Pharmacogenomics, a subset of personalized medicine, focuses on how an individual's genetic makeup influences their response to drugs. AI applications in pharmacogenomics aim to tailor medications based on genetic variations, optimizing treatment efficacy and minimizing adverse effects (Swen et al., 2011). By identifying genetic markers associated with drug metabolism, AI contributes to personalized drug prescriptions (Pirmohamed, 2016; Tula et al., 2024). AI algorithms, particularly machine learning models, are employed in predicting drug efficacy based on individual genetic profiles. These models analyze diverse data, including genetic information, clinical parameters, and treatment outcomes, to generate predictive insights (Peterson et al., 2013; Okoye et al., 2023). Such AI-driven predictions contribute to more informed decision-making in prescribing medications tailored to an individual's genetic makeup (Whirl-Carrillo et al., 2012).

3. AI in patient stratification and clinical trials

AI plays a crucial role in patient stratification, the process of categorizing individuals into specific subgroups based on shared characteristics. Machine learning algorithms analyze complex datasets, including genomic, clinical, and demographic information, to identify patterns that delineate distinct patient subgroups. This enables a more precise understanding of disease heterogeneity and aids in tailoring interventions to specific patient profiles (Lee and Eskin, 2013; Collins and Varmus, 2015). Patient stratification has profound implications for precision medicine, allowing healthcare professionals to target treatments more effectively. AI-driven patient stratification models contribute to the identification of subpopulations that may respond differently to specific therapies. This precision enhances treatment outcomes and reduces the likelihood of adverse effects (Hamburg and Collins, 2010; Schork et al., 2013). AI contributes to optimizing patient recruitment and eligibility in clinical trials. Machine learning models analyze diverse datasets to identify suitable candidates based on specific criteria, including genetic and clinical characteristics. This enhances the efficiency of clinical trial recruitment, accelerates participant selection, and ensures that trial cohorts are representative of the target population (Kahn and Weng, 2012). AI enables adaptive trial designs, where protocols can be dynamically modified based on real-time data. Machine learning algorithms analyze ongoing trial data, allowing for adjustments in treatment arms, dosage, or inclusion criteria (Ukoba and Jen, 2023). Adaptive designs enhance the flexibility and efficiency of clinical trials, increasing the likelihood of successful outcomes (Korn and Freidlin, 2011).

4. AI in disease diagnosis and risk prediction

AI applications in early disease detection leverage advanced algorithms to analyze diverse data sources, including imaging, genomic, and clinical data. Machine learning models can identify subtle patterns indicative of diseases such as cancer, cardiovascular disorders, and neurological conditions. The integration of AI into diagnostic processes enhances accuracy and facilitates earlier intervention. (Esteva et al., 2017; Odunaiya et al., 2024). AI contributes to the development of risk prediction models by incorporating genetic and environmental factors. These models assess an individual's susceptibility to various diseases, enabling proactive measures and personalized preventive strategies (Khera, et al., 2018). The integration of AI in risk prediction aligns with the overarching goal of personalized medicine to tailor interventions based on individualized risk profiles (Inouye et al., 2018). AI facilitates the development of predictive models for treatment response, guiding the customization of treatment plans. By analyzing individual patient data, including genetic information, clinical history, and previous treatment outcomes, AI models can predict how a patient is likely to respond to specific therapeutic interventions (McCarthy et al., 2013).

5. AI in ethical considerations in personalized medicine

The integration of AI in personalized medicine raises concerns about the handling of sensitive genetic and health data. AI algorithms require access to extensive datasets for training and analysis, posing challenges related to data privacy. Robust frameworks for handling, storing, and sharing genetic and health information are essential to safeguard patient privacy (Stranger, 2016). AI applications in personalized medicine must confront the potential for bias in algorithms, especially when applied to diverse populations. Ensuring fairness in the representation of different demographic groups is crucial to prevent disparities in healthcare outcomes (Rajkomar et al.,2018). Ethical considerations include ongoing monitoring, transparency, and efforts to mitigate algorithmic bias (Salazar Reyna, 2019). In the context of personalized medicine, the need for Explainable AI (XAI) is paramount (Combi et al., 2022). Transparent algorithms provide insights into how AI reaches specific conclusions, fostering trust among healthcare professionals, researchers, and patients. XAI is crucial for understanding the rationale behind personalized treatment recommendations (Antoniadi et al., 2021). AI applications in personalized medicine must adhere to rigorous regulatory and ethical guidelines. Regulatory bodies play a crucial role in establishing frameworks for the ethical use of AI, including data privacy, consent, and algorithmic transparency (de Almeida et al., 2021). Adherence to these guidelines is fundamental to ensuring responsible and ethical implementation.

6. Challenges and future directions

The integration of multi-omics data poses a significant challenge in AI-powered personalized medicine (Fawaz et al., 2023). Combining diverse datasets, including genomics, proteomics, and metabolomics, requires advanced analytical methods and interdisciplinary collaboration (Misra et al., 2019). Overcoming these challenges is crucial for realizing the full potential of multi-omics data in improving personalized treatment strategies. The translation of AI-powered personalized medicine from research settings to real-world clinical practice presents implementation challenges (Xu et al., 2019). Bridging the gap between research findings and routine patient care involves addressing issues of scalability, interoperability, and physician training. Collaborative efforts between researchers, clinicians, and policymakers are essential for successful integration. The future of AI-powered personalized medicine hinges on advancements in AI algorithms (Tippur, 2023). Next-generation machine learning and deep learning models are expected to enhance the accuracy and efficiency of predictive analytics. Integration with emerging technologies, such as quantum computing, holds the potential to revolutionize data processing capabilities (Aithal, 2023). International collaboration is essential for advancing the field of AI-powered personalized medicine. Collaborative initiatives for data sharing, standardization of protocols, and joint research efforts can accelerate progress. Global perspectives on ethical, legal, and social implications ensure a comprehensive approach to implementing AI in diverse healthcare ecosystems (Stahl, 2021).

7. Conclusion

The integration of AI in personalized medicine has a transformative impact on patient care. By leveraging advanced analytics and machine learning, healthcare professionals can tailor interventions to individual characteristics, thereby improving treatment outcomes and revolutionizing disease management. As AI continues to shape personalized medicine, an ongoing ethical imperative exists to balance technological advancements with ethical considerations. Addressing issues of privacy, transparency, and bias is essential to ensure that AI applications in personalized medicine adhere to ethical standards.

A collaborative approach involving healthcare professionals, researchers, policymakers, and technology developers is crucial for the ethical implementation of AI in personalized medicine. Stakeholder engagement in ethical decision-making processes and the promotion of responsible AI practices ensure a collective commitment to ethical standards. Anticipating future developments in AI and personalized medicine requires a proactive stance. Embracing ethical guidelines, fostering interdisciplinary collaboration, and staying attuned to global perspectives will contribute to shaping a responsible and equitable future in personalized healthcare. This comprehensive exploration of AI applications in personalized medicine, spanning from patient stratification to ethical considerations and future directions, underscores the multifaceted impact of AI on the future of healthcare. The referenced literature provides a foundation for continued research, innovation, and ethical implementation in the evolving landscape of personalized medicine.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Aithal, P. S. (2023). Advances and new research opportunities in quantum computing technology by integrating it with other ICCT underlying technologies. International Journal of Case Studies in Business, IT and Education (IJCSBE), 7(3), 314-358.

[2] Antoniadi, A. M., Du, Y., Guendouz, Y., Wei, L., Mazo, C., Becker, B. A., & Mooney, C. (2021). Current challenges and future opportunities for XAI in machine learning-based clinical decision support systems: a systematic review. Applied Sciences, 11(11), 5088.

[3] Char, D. S., Shah, N. H., & Magnus, D. (2018). Implementing Machine Learning in Health Care-Addressing Ethical Challenges. New England Journal of Medicine, 378(11), 981-983.

[4] Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New England Journal of Medicine, 372(9), 793-795.

[5] Combi, C., Amico, B., Bellazzi, R., Holzinger, A., Moore, J. H., Zitnik, M., & Holmes, J. H. (2022). A manifesto on explainability for artificial intelligence in medicine. Artificial Intelligence in Medicine, 133, 102423.

[6] de Almeida, P. G. R., dos Santos, C. D., & Farias, J. S. (2021). Artificial intelligence regulation: a framework for governance. Ethics and Information Technology, 23(3), 505-525.

[7] Duffy, D. J. (2016). Problems, challenges and promises: perspectives on precision medicine. Briefings in bioinformatics, 17(3), 494-504.

[8] Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., ... & Dean, J. (2019). A guide to deep learning in healthcare. Nature medicine, 25(1), 24-29.

[9] Fawaz, A., Ferraresi, A., & Isidoro, C. (2023). Systems Biology in Cancer Diagnosis Integrating Omics Technologies and Artificial Intelligence to Support Physician Decision Making. Journal of Personalized Medicine, 13(11), 1590.

[10] Ginsburg, G. S., & McCarthy, J. J. (2001). Personalized medicine: revolutionizing drug discovery and patient care. Trends in Biotechnology, 19(12), 491-496.

[11] Green, E. D., Gunter, C., Biesecker, L. G., Di Francesco, V., Easter, C. L., Feingold, E. A., ... & Manolio, T. A. (2020). Strategic vision for improving human health at The Forefront of Genomics. Nature, 586(7831), 683-692.

[12] Hamburg, M. A., & Collins, F. S. (2010). The path to personalized medicine. New England Journal of Medicine, 363(4), 301-304.

[13] Inouye, M., Abraham, G., Nelson, C. P., Wood, A. M., Sweeting, M. J., Dudbridge, F., ... & UK Biobank CardioMetabolic Consortium CHD Working Group. (2018). Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention. Journal of the American College of Cardiology, 72(16), 1883-1893.

[14] Jameson, J. L., & Longo, D. L. (2015). Precision medicine—personalized, problematic, and promising. New England Journal of Medicine, 372(23), 2229-2234.

[15] Johnson, K. B., Wei, W. Q., Weeraratne, D., Frisse, M. E., Misulis, K., Rhee, K., ... & Snowdon, J. L. (2021). Precision medicine, AI, and the future of personalized health care. Clinical and translational science, 14(1), 86-93.

[16] Kahn, M. G., & Weng, C. (2012). Clinical research informatics: a conceptual perspective. Journal of the American Medical Informatics Association, 19(e1), e36-e42.

[17] Keerthana, G., Revathi, M. P., Ambika, M., & Usharani, P. (2020). UNLOCKING GENETIC INSIGHTS: EXPLORING THE POTENTIAL OF AI SYSTEMS IN GENE ANALYSIS. NeuroQuantology, 18(8), 224.

[18] Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., ... & Kathiresan, S. (2018). Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nature genetics, 50(9), 1219-1224.

[19] Korn, E. L., & Freidlin, B. (2011). Adaptive clinical trials: advantages and disadvantages of various adaptive design elements. Journal of the National Cancer Institute, 103(22), 1666-1670.

[20] Krittanawong, C., Johnson, K. W., Hershman, S. G., & Tang, W. W. (2018). Big data, artificial intelligence, and cardiovascular precision medicine. Expert Review of Precision Medicine and Drug Development, 3(5), 305-317.

[21] Lee, S. I., & Eskin, E. (2013). Population stratification correction in genome-wide association studies. PLoS ONE, 8(2), e65487.

[22] McCarthy, J. J., McLeod, H. L., & Ginsburg, G. S. (2013). Genomic medicine: a decade of successes, challenges, and opportunities. Science translational medicine, 5(189), 189sr4-189sr4.

[23] Misra, B. B., Langefeld, C., Olivier, M., & Cox, L. A. (2019). Integrated omics: tools, advances and future approaches. Journal of molecular endocrinology, 62(1), R21-R45.

[24] Nwankwo E. E., Ogedengbe D. E., Oladapo J. O., Soyombo O. T., and Okoye C. C. (2024). Cross-cultural leadership styles in multinational corporations: A comparative literature review. International Journal of Science and Research Archives (IJSRA). DOI: https://doi.org/10.30574/ijsra.2024.11.1.0273

[25] Odunaiya O. G., Nwankwo E. E., Okoye C.C., and Uzondu C. S. (2024). Behavioral economics and consumer protection in the U.S.: A review: Understanding how psychological factors shape consumer policies and regulations. International Journal of Science and Research Archives. (IJSRA). DOI: https://doi.org/10.30574/ijsra.2024.11.1.0274

[26] Okoye C. C., Nwankwo D. O., Okeke N. M., Nwankwo E. E., Eze S. U., (2023). Electronic commerce and sustainability of SMEs in Anambra State, Malaysian E Commerce Journal (MECJ), https://myecommerecejournal.com/archives/mecj-01-2023-32-41/

[27] Oladipo J. O., Okoye C. C., Elufioye O. A., Falaiye T., and Nwankwo E. E. (2024). Human factors in cybersecurity: Navigating the fintech landscape. International Journal of Science and Research Archives (IJSRA). DOI: https://doi.org/10.30574/ijsra.2024.11.1.0258

[28] Peterson, T. A., Doughty, E., & Kann, M. G. (2013). Towards precision medicine: advances in computational approaches for the analysis of human variants. Journal of molecular biology, 425(21), 4047-4063.

[29] Pirmohamed, M. (2016). Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annual Review of Genomics and Human Genetics, 17, 65-95.

[30] Poplin, R., et al. (2018). A universal SNP and small-indel variant caller using deep neural networks. Nature Biotechnology, 36(10), 983-987.

[31] Rajkomar, A., Hardt, M., Howell, M. D., Corrado, G., & Chin, M. H. (2018). Ensuring fairness in machine learning to advance health equity. Annals of internal medicine, 169(12), 866-872.

[32] Salazar Reyna, R. J. (2019). Systematic Literature Review of Data Science, Data Analytics and Machine Learning Applied into Healthcare Engineering Systems.

[33] Schork, A. J., Thompson, W. K., Pham, P., Torkamani, A., Roddey, J. C., Sullivan, P. F., ... & Dale, A. M. (2013). All SNPs are not created equal: genome-wide association studies reveal a consistent pattern of enrichment among functionally annotated SNPs. PLoS genetics, 9(4), e1003449.

[34] Schuster, S. C. (2008). Next-generation sequencing transforms today's biology. Nature Methods, 5(1), 16-18.

[35] Seyhan, A. A., & Carini, C. (2019). Are innovation and new technologies in precision medicine paving a new era in patients centric care?. Journal of translational medicine, 17, 1-28.

[36] Shendure, J., & Ji, H. (2008). Next-generation DNA sequencing. Nature Biotechnology, 26(10), 1135-1145.

[37] Stahl, B. C. (2021). Artificial intelligence for a better future: an ecosystem perspective on the ethics of AI and emerging digital technologies (p. 124). Springer Nature.

[38] Stranger, M. (2016). Principles and practice in biobank governance. Routledge.

[39] Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., ... & Guchelaar, H. J. (2011). Pharmacogenetics: from bench to byte—an update of guidelines. Clinical Pharmacology & Therapeutics, 89(5), 662-673.

[40] Tippur, A. (2023). AI-Powered Precision Oncology: Computational Insights Redefining Therapeutic Landscapes. DHR Proceedings, 3(S1), 1-10.

[41] Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 25(1), 44-56.

[42] Tula S. T., Ofodile O. C., Okoye C. C., Nifise A. O. A., and Odeyemi O. (2024). Entrepreneurial ecosystems in the USA: A comparative review with European models. International Journal of Management & Entrepreneurship Research. DOI: 10.51594/ijmer.v6i

[43] Ukoba, K. and Jen, T.C., 2023. Thin films, atomic layer deposition, and 3D Printing: demystifying the concepts and their relevance in industry 4.0. CRC Press.

[44] Verma, M. (2012). Personalized medicine and cancer. Journal of personalized medicine, 2(1), 1-14.

[45] Whirl-Carrillo, M., McDonagh, E. M., Hebert, J. M., Gong, L., Sangkuhl, K., Thorn, C. F., ... & Klein, T. E. (2012). Pharmacogenomics knowledge for personalized medicine. Clinical Pharmacology & Therapeutics, 92(4), 414-417.

[46] Xu, J., Yang, P., Xue, S., Sharma, B., Sanchez-Martin, M., Wang, F., ... & Parikh, B. (2019). Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives. Human genetics, 138(2), 109-124.

[47] Zou, J., Huss, M., Abid, A., Mohammadi, P., Torkamani, A., & Telenti, A. (2019). A primer on deep learning in genomics. Nature genetics, 51(1), 12-18.